Patents by Inventor Hubert Heuer

Hubert Heuer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9029400
    Abstract: The present invention relates to 5-oxoisoxazole derivatives of the formula I, the pharmaceutically usable salts thereof and the use thereof as medicinal substances.
    Type: Grant
    Filed: October 5, 2009
    Date of Patent: May 12, 2015
    Assignee: Sanofi
    Inventors: Stefan Petry, Manfred Seidel, Gerhard Zoller, Gunter Müller, Karl-Heinz Baringhaus, Hubert Heuer
  • Patent number: 8921404
    Abstract: The invention relates to azole derivatives of the general formula I as defined in the present application as well as to their uses in treatment of conditions that would benefit from their inhibitory effect on hormone sensitive lipase, HSL, an allosteric enzyme in adipocytes which is inhibited by insulin and is responsible for the breakdown of fats in fat cells and thus for transferring fat constituents into the blood stream. Inhibition of this enzyme is therefore equivalent to an insulin-like effect of the compounds of the invention.
    Type: Grant
    Filed: October 17, 2007
    Date of Patent: December 30, 2014
    Assignee: Sanofi
    Inventors: Gerhard Zoller, Stefan Petry, Gunter Muller, Hubert Heuer, Norbert Tennagels
  • Patent number: 8748483
    Abstract: The invention relates to the use of substituted pyranone acid derivatives and of their physiologically acceptable salts for producing medicaments for treating the metabolic syndrome.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: June 10, 2014
    Assignee: SANOFI
    Inventors: Harm Brummerhop, Siegfried Stengelin, Hubert Heuer, Susanne Kilp, Andreas Herling, Thomas Klabunde, Dieter Kadereit, Matthias Urmann
  • Patent number: 8357698
    Abstract: The invention relates to diacyl indazole derivatives of general formulae (I) or (II) and to the pharmaceutically acceptable salts thereof: Wherein X, R1 and R2 are as defined herein. The invention also relates to the use of these compounds to treat diabetes mellitus, dyslipidemia and atherosclerotic disorders.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: January 22, 2013
    Assignee: Sanofi
    Inventors: Gerhard Zoller, Stefan Petry, Gunter Muller, Hubert Heuer, Norbert Tennagels
  • Patent number: 8222240
    Abstract: The present invention comprises methods for reducing plasma lipids, plasma free fatty acids (FFA), plasma glycerol and triglycerides in a mammal through the administration of certain substituted cyclopropane acid derivatives of Formula 1: wherein R1-R6 are defined herein and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: December 4, 2008
    Date of Patent: July 17, 2012
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Dieter Kadereit, Siegfried Stengelin, Hubert Heuer, Harm Brummerhop
  • Patent number: 8106023
    Abstract: This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives with improved properties, method for producing the same, drugs containing said compounds and use thereof.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: January 31, 2012
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heiner Glombik, Wendelin Frick, Stefan Theis, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer
  • Patent number: 8101583
    Abstract: This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with fluorine, method for producing the same, drugs containing said compounds and use thereof.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: January 24, 2012
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heiner Glombik, Wendelin Frick, Stefan Theis, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer
  • Patent number: 8008331
    Abstract: The invention relates to benzothiazol-2-one derivatives of general formula (I) with the meanings indicated in the description, the pharmaceutically usable salts thereof, and the use thereof as medicinal substances.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: August 30, 2011
    Assignee: Sanofi-Aventis
    Inventors: Gerhard Zoller, Stefan Petry, Gunter Müller, Hubert Heuer, Norbert Tennagels
  • Patent number: 7968719
    Abstract: The present invention relates to indazole derivatives of the general formulae I or II having the meanings indicated in the description, to the pharmaceutically useful salts thereof and the use thereof as drugs.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: June 28, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Gerhard Zoller, Stefan Petry, Gunter Muller, Hubert Heuer, Karl-Heinz Baringhaus
  • Patent number: 7956085
    Abstract: This invention relates to Novel 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: June 7, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Wendelin Frick, Heiner Glombik, Stefan Theis, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer
  • Patent number: 7923468
    Abstract: This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with cyclohexyl groups, method for producing the same, drugs containing said compounds and use thereof.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: April 12, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Wendelin Frick, Heiner Glombik, Stefan Theis, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer
  • Publication number: 20110039883
    Abstract: The present invention provides compounds which have an inhibitory effect on hormone-sensitive lipase or endothelial lipase. The compounds of the invention are azolopyridin-2-one derivatives of the general formula I wherein the substituents are as defined herein. The compounds of formula I wherein R2 is hydrogen are distinguished by favorable effects on disorders of lipid metabolism. They beneficially influence the HDL to LDL ratio and increase in particular the HDL level and are suitable for the prevention and treatment of dyslipidemias and metabolic syndrome and their diverse sequelae such as atherosclerosis, coronary heart disease, heart failure, obesity and diabetes. The compounds of formula I wherein R1 and R2 together form a ring system are distinguished by favorable effects on metabolic disorders.
    Type: Application
    Filed: October 28, 2010
    Publication date: February 17, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Gerhard Zoller, Stefan Petry, Gunter Müller, Hubert Heuer, Norbert Tennagels
  • Patent number: 7846943
    Abstract: The present invention provides compounds which have an inhibitory effect on hormone-sensitive lipase or endothelial lipase. The compounds of the invention are azolopyridin-2-one derivatives of the general formula I wherein the substituents are as defined herein. The compounds of formula I wherein R2 is hydrogen are distinguished by favorable effects on disorders of lipid metabolism. They beneficially influence the HDL to LDL ratio and increase in particular the HDL level and are suitable for the prevention and treatment of dyslipidemias and metabolic syndrome and their diverse sequelae such as atherosclerosis, coronary heart disease, heart failure, obesity and diabetes. The compounds of formula I wherein R1 and R2 together form a ring system are distinguished by favorable effects on metabolic disorders.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: December 7, 2010
    Assignee: Sanofi-Aventis
    Inventors: Gerhard Zoller, Stefan Petry, Gunter Müller, Hubert Heuer, Norbert Tennagels
  • Publication number: 20100286133
    Abstract: The invention relates to diacyl indazole derivatives of general formulae (I) or (II) and to the pharmaceutically acceptable salts thereof: Wherein X, R1 and R2 are as defined herein. The invention also relates to the use of these compounds as pharmaceutical products.
    Type: Application
    Filed: July 20, 2010
    Publication date: November 11, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Gerhard ZOLLER, Stefan PETRY, Gunter MÜLLER, Hubert HEUER, Norbert TENNAGELS
  • Patent number: 7820804
    Abstract: The invention relates to substituted fluoroglycoside derivatives of pyrazoles of formula (I) as further defined in the specification, to the physiologically compatible salts thereof, to a method for their production, and to their use as antidiabetics.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: October 26, 2010
    Assignee: Sanofi-Aventia Deutschland GmbH
    Inventors: Harm Brummerhop, Wendeline Frick, Heiner Glombik, Oliver Plettenburg, Martin Bickel, Hubert Heuer, Stefan Theis
  • Publication number: 20100261664
    Abstract: Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof The invention relates to substituted heterocyclic fluoroglycoside derivatives of the formula I in which the radicals have the stated meanings, and their physiologically tolerated salts and processes for their preparation. The compounds are suitable for example as antidiabetics.
    Type: Application
    Filed: May 25, 2010
    Publication date: October 14, 2010
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Wendelin FRICK, Heiner GLOMBIK, Werner KRAMER, Hubert HEUER, Harm BRUMMERHOP, Oliver PLETTENBURG
  • Patent number: 7772268
    Abstract: The invention relates to diacyl indazole derivatives of general formulae (I) or (II) and to the pharmaceutically acceptable salts thereof: Wherein X, R1 and R2 are as defined herein. The invention also relates to the use of these compounds to treat diabetes mellitus, dyslipidemia and atherosclerotic disorders.
    Type: Grant
    Filed: April 8, 2008
    Date of Patent: August 10, 2010
    Assignee: Sanofi-Aventis
    Inventors: Gerhard Zoller, Stefan Petry, Gunter Müller, Hubert Heuer, Norbert Tennagels
  • Patent number: 7772429
    Abstract: The invention relates to the compound of the formula 1 and to its physiologically acceptable salts. The compound is suitable, for example, as a hypolipidemic.
    Type: Grant
    Filed: March 26, 2007
    Date of Patent: August 10, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Gerhard Jaehne, Wendelin Frick, Andreas Lindenschmidt, Stefanie Flohr, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer, Eric Galia, Heiner Glombik
  • Publication number: 20100190801
    Abstract: The invention relates to triazolopyridine derivatives of general formula (I), which are defined as cited in the description, to their pharmaceutically applicable salts and to their use as medicaments.
    Type: Application
    Filed: March 25, 2010
    Publication date: July 29, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Stefan PETRY, Gerhard ZOLLER, Günter MÜLLER, Karl-Heinz BARINGHAUS, Hubert HEUER
  • Publication number: 20100173961
    Abstract: The invention relates to benzooxazol-2-one derivatives of general formula (I) with the meanings indicated in the description, the pharmaceutically usable salts thereof, and the use thereof as medicinal substances.
    Type: Application
    Filed: March 18, 2010
    Publication date: July 8, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Gerhard ZOLLER, Stefan PETRY, Gunter MÜLLER, Hubert HEUER, Norbert TENNAGELS